Nasdaq
$9.58▼ 0.31%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $850.5MShares out 88.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
29- 9.29After-hours26.09.30 07:304Ownership#●●●
Kura Oncology, Inc.
Teresa Brophy Bair, an executive at Kura Oncology, Inc., filed a Form 4 report regarding changes in beneficial ownership of securities as of September 28, 2026. This filing serves as a standard disclosure of insider equity movement.…more
$9.58-0.31%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.29After-hours26.09.30 07:304Ownership
Kura Oncology, Inc.
Kura Oncology insider Kathleen Ford reported a change in beneficial ownership of securities as of September 28, 2026. This filing is a standard disclosure of insider equity movement and does not contain any material information regarding corporate financing or listing status.…more
$9.58-0.31%vs prev closeView filingShare - 9.29After-hours26.09.30 07:304Ownership
Kura Oncology, Inc.
Insider Mollie Leoni of Kura Oncology reported a change in beneficial ownership of securities as of September 28, 2026. This filing provides the details of the insider's equity transaction via Form 4.…more
$9.58-0.31%vs prev closeView filingShare
28 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.13Pre-market26.10.13 20:30#●●●#●●●#●●●
Kura Oncology Outlines Development Strategy for Diabetes Candidate KO-7246…more
Kura Oncology and its subsidiary Caspian Therapeutics presented preclinical data and the development roadmap for their diabetes drug candidate, KO-7246. The announcement focuses on outlining the path toward clinical proof-of-concept studies for the novel menin inhibitor.…more
$9.58-0.31%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.7Pre-market26.10.07 20:15
●●●●●●●● ●●●●● ●●●●●●
Kura Oncology and Caspian Therapeutics will host an investor webcast to review preclinical data for the diabetes drug candidate KO-7246. As the event focuses on sharing development updates without immediate financial or regulatory milestones, it is considered a neutral event.…more
$9.58-0.31%vs prev close - 10.2Pre-market26.10.02 20:30
●●●●●●●● ●●●●● ●●●●●●
Kura Oncology has granted nonstatutory stock options for 128,250 shares to nine new employees as an inducement for their employment. These grants are subject to a four-year vesting schedule and may result in future share dilution.…more
$9.58-0.31%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report